Has it come to the time to recommend routine use of alirocumab in patients with acute coronary syndrome?
| Errataetall: |
CommentOn: Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. - PMID 33755145 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
European journal of preventive cardiology - 29(2022), 2 vom: 11. März, Seite e77-e78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alirocumab |
|---|
| Anmerkungen: |
Date Completed 05.04.2022 Date Revised 05.04.2022 published: Print CommentOn: Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. - PMID 33755145 Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurjpc/zwaa148 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321824261 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321824261 | ||
| 003 | DE-627 | ||
| 005 | 20231225180719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurjpc/zwaa148 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321824261 | ||
| 035 | |a (NLM)33624099 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Has it come to the time to recommend routine use of alirocumab in patients with acute coronary syndrome? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2022 | ||
| 500 | |a Date Revised 05.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Eur J Prev Cardiol. 2021 Mar 23;28(1):33-43. - PMID 33755145 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Anticholesteremic Agents |2 NLM | |
| 650 | 7 | |a alirocumab |2 NLM | |
| 650 | 7 | |a PP0SHH6V16 |2 NLM | |
| 700 | 1 | |a Zaihan, Abdullah Faiz |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of preventive cardiology |d 2012 |g 29(2022), 2 vom: 11. März, Seite e77-e78 |w (DE-627)NLM19817909X |x 2047-4881 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:2 |g day:11 |g month:03 |g pages:e77-e78 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurjpc/zwaa148 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 2 |b 11 |c 03 |h e77-e78 | ||